Sanofi SA Company Profile (EPA:SAN)

About Sanofi SA (EPA:SAN)

Sanofi SA logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: EPA:SAN
  • CUSIP: N/A
  • Web: en.sanofi.com
Average Prices:
  • 50 Day Moving Avg: €25.48
  • 200 Day Moving Avg: €25.74
P/E:
  • Trailing P/E Ratio: 11.47
  • P/E Growth: 2.25
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 14.63%
 

Frequently Asked Questions for Sanofi SA (EPA:SAN)

What is Sanofi SA's stock symbol?

Sanofi SA trades on the EPA under the ticker symbol "SAN."

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

16 brokerages have issued 12-month target prices for Sanofi SA's stock. Their forecasts range from €75.00 to €100.00. On average, they anticipate Sanofi SA's stock price to reach €88.00 in the next year. View Analyst Ratings for Sanofi SA.

Who are some of Sanofi SA's key competitors?

Who are Sanofi SA's key executives?

Sanofi SA's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team


MarketBeat Community Rating for Sanofi SA (EPA SAN)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  335 (Vote Outperform)
Underperform Votes:  406 (Vote Underperform)
Total Votes:  741
MarketBeat's community ratings are surveys of what our community members think about Sanofi SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi SA (EPA:SAN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: €88.00

Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetDetails
8/7/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral€82.00View Rating Details
8/1/2017Deutsche Bank AGSet Price TargetBuy€96.00View Rating Details
8/1/2017J P Morgan Chase & CoSet Price TargetNeutral€90.00View Rating Details
7/31/2017Sanford C. BernsteinSet Price TargetNeutral€90.00View Rating Details
7/31/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
7/31/2017S&P GlobalSet Price TargetNeutral€90.00View Rating Details
7/26/2017Kepler Capital MarketsSet Price TargetBuy€89.00View Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
6/16/2017Jefferies Group LLCSet Price TargetNeutral€90.00View Rating Details
6/6/2017Morgan StanleySet Price TargetBuy€91.00View Rating Details
5/8/2017Barclays PLCSet Price TargetSell€75.00View Rating Details
4/7/2017HSBC Holdings plcSet Price TargetSell€77.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
1/6/2017Citigroup Inc.Reiterated RatingNeutralView Rating Details
12/6/2016S&P Global Inc.Set Price TargetNeutral€80.00View Rating Details
9/14/2016BNP ParibasSet Price TargetNeutral€78.00View Rating Details
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 8/23/2015 forward)

Earnings

Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sanofi SA (EPA:SAN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)
Source:
DateHeadline
finance.yahoo.com logoPerformance of Sanofi’s Established Products in 2Q17
finance.yahoo.com - August 19 at 7:15 AM
finance.yahoo.com logoSanofi’s General Medicines and Consumer Healthcare in 2Q17
finance.yahoo.com - August 19 at 7:15 AM
finance.yahoo.com logoA Look at Sanofi Pasteur’s Performance in 2Q17
finance.yahoo.com - August 19 at 7:15 AM
benzinga.com logoWhere Does Zika Virus Vaccine Research Stand Now? - Benzinga
www.benzinga.com - August 14 at 3:00 AM
reuters.com logoMexico watchdog finds big pharma faces no competition on some ... - Reuters
www.reuters.com - August 10 at 7:39 AM
News IconCVS Health's dull third-quarter forecast overshadows profit beat - Business Insider
www.businessinsider.com - August 9 at 7:09 AM
finance.yahoo.com logoSanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
finance.yahoo.com - August 9 at 7:09 AM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (SAN) a €82.00 Price Target
www.americanbankingnews.com - August 7 at 9:20 PM
benzinga.com logoThis Week's Pharma, Energy IPOs - Benzinga
www.benzinga.com - August 7 at 3:18 PM
americanbankingnews.com logoSanofi SA (SAN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 4 at 10:44 AM
reuters.com logoRegeneron beats profit view, to end antibody deal with Sanofi - Reuters
www.reuters.com - August 4 at 7:51 AM
finance.yahoo.com logoRegeneron quarterly profit nearly doubles
finance.yahoo.com - August 4 at 7:51 AM
finance.yahoo.com logoRegeneron: Wait, I Thought It Was Good News?!?!
finance.yahoo.com - August 4 at 7:51 AM
nasdaq.com logoEurope ETF (EZU) Hits New 52-Week High - Nasdaq
www.nasdaq.com - August 2 at 10:30 PM
thestreet.com logoSanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook - TheStreet.com
www.thestreet.com - August 2 at 7:28 AM
americanbankingnews.com logoDeutsche Bank AG Reiterates "€96.00" Price Target for Sanofi SA (EPA:SAN)
www.americanbankingnews.com - August 1 at 12:56 PM
seekingalpha.com logoSanofi (SNY) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 1 at 6:10 AM
rttnews.com logoSanofi Q2 Profit Down, Sales Rise; Lifts FY17 Earnings View; Stock Up
www.rttnews.com - August 1 at 6:10 AM
finance.yahoo.com logoBiotech Is Only Expensive When You Follow the Crowd
finance.yahoo.com - August 1 at 6:10 AM
finance.yahoo.com logoPraluent Could Witness Steady Growth in 2017
finance.yahoo.com - August 1 at 6:10 AM
finance.yahoo.com logoEdited Transcript of SAN.PA earnings conference call or presentation 31-Jul-17 12:30pm GMT
finance.yahoo.com - August 1 at 6:10 AM
finance.yahoo.com logoSanofi meets 2Q profit forecasts
finance.yahoo.com - August 1 at 6:10 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €97.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - July 31 at 12:21 PM
americanbankingnews.com logoSanford C. Bernstein Analysts Give Sanofi SA (EPA:SAN) a €90.00 Price Target
www.americanbankingnews.com - July 31 at 11:11 AM
nasdaq.com logoSanofi Q2 Profit Declines, Sales Rise; Lifts FY17 Business EPS View - Nasdaq
www.nasdaq.com - July 31 at 2:30 AM
finance.yahoo.com logoSanofi Raises FY 2017 Business EPS(1) Guidance to Broadly Stable at CER(2)
finance.yahoo.com - July 31 at 2:30 AM
finance.yahoo.com logoGreen River (City of) WY, Variable Rate Demand Revenue Bonds (Rhone-Poulenc of Wyoming, L.P. Project), Series 1994, $11.4MM -- Moody's Affirms A1/VMIG 1 on Green River, WY's LOC-backed VRDBs (Rhone-Poulenc of WY, L.P.) Series 1994
finance.yahoo.com - July 28 at 7:35 AM
americanbankingnews.com logoSanofi SA (EPA:SAN) Given a €82.00 Price Target at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - July 26 at 9:38 AM
News IconUPDATE 1-US jury sides with Amphastar over Momenta in drug patent trial - Business Insider
www.businessinsider.com - July 22 at 8:30 AM
reuters.com logoFDA tentatively approves Merck's copycat of Sanofi's Lantus - Reuters
www.reuters.com - July 21 at 6:52 AM
americanbankingnews.com logoSanofi SA (SAN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 20 at 10:53 AM
bloomberg.com logoRoad to Brexit: The Heartlands Where a Good Deal Matters Most - Bloomberg
www.bloomberg.com - July 13 at 9:08 AM
finance.yahoo.com logoSanofi: Pre-quarterly Results Communication
finance.yahoo.com - July 13 at 9:08 AM
reuters.com logoSanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed
www.reuters.com - July 12 at 7:42 AM
thestreet.com logoSanofi Steps Up M&A Activity With $650 Million Purchase of Protein Sciences - TheStreet.com
www.thestreet.com - July 12 at 7:42 AM
reuters.com logoSanofi lawsuit over Novo Nordisk diabetes drug marketing narrowed - Reuters
www.reuters.com - July 12 at 7:42 AM
prnewswire.com logoChronic Kidney Disease (CKD) Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 7:23 AM
marketwatch.com logoSanofi to buy vaccine maker Protein Sciences - MarketWatch
www.marketwatch.com - July 11 at 7:23 AM
finance.yahoo.com logoEuropean stocks stuck in tight ranges as traders wait for Yellen
finance.yahoo.com - July 11 at 7:23 AM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - July 10 at 11:14 AM
finance.yahoo.com logoAlnylam Pharmaceuticals, Inc. Stock Perked Up 14% in June -- Here's Why
finance.yahoo.com - July 7 at 9:42 AM
reuters.com logoPfizer receives token payment to exit Brazil venture, sources say ... - Reuters
www.reuters.com - July 6 at 8:46 AM
News IconPfizer receives token payment to exit Brazil venture, sources say - Business Insider
www.businessinsider.com - July 5 at 10:20 AM
americanbankingnews.com logoCredit Suisse Group Analysts Give Sanofi SA (SAN) a €95.00 Price Target
www.americanbankingnews.com - July 4 at 7:25 AM
bloomberg.com logoBuoyant Europe Stocks Turn Out to Be `Pain Trade' of First Half - Bloomberg
www.bloomberg.com - July 1 at 7:12 AM
nasdaq.com logoIMF Lowers US Growth Outlook: International ETFs to Buy - Nasdaq
www.nasdaq.com - June 29 at 6:43 AM
bloomberg.com logoDomino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move - Bloomberg
www.bloomberg.com - June 27 at 8:02 AM
finance.yahoo.com logoSanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union
finance.yahoo.com - June 27 at 8:02 AM
finance.yahoo.com logoGood Companies From Warren Buffett's Portfolio
finance.yahoo.com - June 25 at 8:07 PM
nasdaq.com logoGood Companies From Warren Buffett's Portfolio - Nasdaq.com - Nasdaq
www.nasdaq.com - June 25 at 5:33 AM

Social

Social activity is not available for this stock.
This page was last updated on 8/23/2017 by MarketBeat.com Staff